Clinical implications of 18F-sodium fluoride uptake in subclinical aortic valve calcification: Its relation to coronary atherosclerosis and its predictive value
Clinical implications of 18F-sodium fluoride uptake in subclinical aortic valve calcification: Its relation to coronary atherosclerosis and its predictive value
复制标题
DOI:
10.1007/s12350-019-01879-6
复制
发表时间:
2021-08-01
影响因子:
2.4
通讯作者:
Kihara, Yasuki
中科院分区:
文献类型:
--
作者:
Nakamoto, Yumiko;Kitagawa, Toshiro;Kihara, Yasuki
Background Uptake of F-18-sodium fluoride (F-18-NaF) on positron emission tomography (PET) reflects active calcification. Application of this technique in the early phase of aortic valve calcification (AVC) is of clinical interest. We investigated clinical implications of F-18-NaF uptake in subclinical AVC evaluated simultaneously with coronary atherosclerosis, and the utility of F-18-NaF uptake in predicting AVC progression. Methods We studied 25 patients with subclinical AVC and coronary plaques detected on computed tomography (CT) who underwent F-18-NaF PET/CT. AVC score, volume, mean density, and the presence of high-risk coronary plaque were evaluated on CT in each patient. Focal F-18-NaF uptake in AVC and in coronary plaques was quantified with the maximum tissue-to-background ratio (TBRmax). Results There were positive correlations between AVC TBRmax (A-TBRmax) and AVC parameters on CT. The 14 patients with high-risk coronary plaque had significantly higher A-TBRmax than those without such plaque (1.60 +/- 0.18 vs 1.42 +/- 0.13, respectively; P = 0.012). A-TBRmax positively correlated with maximum TBRmax of coronary plaque per patient (r = 0.55, P = 0.0043). In the 11 patients who underwent follow-up CT scan, A-TBRmax positively correlated with subsequent increase in AVC score (r = 0.74, P = 0.0091). Conclusion Our F-18-NaF PET- and CT-based data indicate relationships between calcification activity in subclinical AVC and characteristics of coronary atherosclerosis. F-18-NaF PET may provide new information regarding molecular conditions and future progression of subclinical AVC.